Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18906375 | 1.00 | BLM (0.35) | BLMPMP22HSD17B10CA12CA1 | |
| SCHEMBL25143061 | 0.91 | APLNR (0.36) | CA12CA1CA7CA14APLNR | |
| SCHEMBL17337904 | 0.91 | APLNR (0.36) | CA12CA1CA7CA14APLNR | |
| SCHEMBL16133570 | 0.91 | APLNR (0.36) | CA12CA1CA7CA14APLNR | |
| SCHEMBL17301885 | 0.91 | APLNR (0.36) | CA12CA1CA7CA14APLNR | |
| SCHEMBL20151957 | 0.91 | APLNR (0.36) | CA12CA1CA7CA14APLNR | |
| SCHEMBL17926776 | 0.91 | APLNR (0.36) | CA12CA1CA7CA14APLNR | |
| SCHEMBL18906929 | 0.85 | CA12 (0.31) | CA12CA1CA7CA14APLNR | |
| SCHEMBL5494091 | 0.84 | APLNR (0.40) | CA12CA1CA7CA14APLNR | |
| SCHEMBL18906376 | 0.81 | BLM (0.30) | BLMPMP22HSD17B10CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220218840-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING BRANCHED LINKERS AND METHODS RELATED THERETO | LIGACHEM BIOSCIENCES INC. (KR) | 2022-07-14 | — | — | US | disclosed |
| US-11173214-B2 | Antibody-drug conjugates comprising branched linkers and methods related thereto | LEGOCHEM BIOSCIENCES, INC. (KR) | 2021-11-16 | — | — | US | disclosed |
| US-11167040-B2 | Conjugates comprising peptide groups and methods related thereto | LEGOCHEM BIOSCIENCES, INC. (KR) | 2021-11-09 | — | — | US | disclosed |
| US-20200297865-A1 | CONJUGATES COMPRISING SELF-IMMOLATIVE GROUPS AND METHODS RELATED THERETO | LIGACHEM BIOSCIENCES INC. (KR) | 2020-09-24 | — | — | US | disclosed |
| US-20190151465-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING BRANCHED LINKERS AND METHODS RELATED THERETO | LIGACHEM BIOSCIENCES INC. (KR) | 2019-05-23 | — | — | US | disclosed |
| WO-2017089895-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING BRANCHED LINKERS AND METHODS RELATED THERETO | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-06-01 | — | — | WO | disclosed |
| WO-2017089894-A1 | CONJUGATES COMPRISING PEPTIDE GROUPS AND METHODS RELATED THERETO | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-06-01 | — | — | WO | disclosed |
| WO-2017089890-A1 | CONJUGATES COMPRISING SELF-IMMOLATIVE GROUPS AND METHODS RELATED THERETO | LEGOCHEM BIOSCIENCES, INC. (KR) | 2017-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190151465-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING BRANCHED LINKERS AND METHODS RELATED THERETO | PA2G4, FCGRT, CLTB | BLM 2284/4885PMP22 2673/4885HSD17B10 1925/4885 |
| US-11167040-B2 | Conjugates comprising peptide groups and methods related thereto | DAO, LPO, TYRO3 | BLM 3087/4885PMP22 1634/4885HSD17B10 3496/4885 |
| US-11173214-B2 | Antibody-drug conjugates comprising branched linkers and methods related thereto | PA2G4, FCGRT, CLTB | BLM 2284/4885PMP22 2673/4885HSD17B10 1925/4885 |
| US-20200297865-A1 | CONJUGATES COMPRISING SELF-IMMOLATIVE GROUPS AND METHODS RELATED THERETO | LPO, NOXO1, DAO | BLM 3047/4885PMP22 1521/4885HSD17B10 1801/4885 |
| US-20220218840-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING BRANCHED LINKERS AND METHODS RELATED THERETO | PA2G4, FCGRT, CLTB | BLM 2284/4885PMP22 2673/4885HSD17B10 1925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.